Intralesional Injection of Acyclovir Versus Candida Antigen in Treatment of Plantar Warts
Acyclovir and Candida Antigen in Treatment of Plantar Wart
About this trial
This is an interventional treatment trial for Acyclovir and Candida Antigen in Treatment of Plantar Wart focused on measuring acyclovir ,candida antigen ,plantar wart
Eligibility Criteria
Inclusion Criteria:
- The study will include patients with single or multiple planter wart. Age group 18:50 years old
Exclusion Criteria:
- : patients with history of renal or liver disease, pregnant and lactating females, patients taking immunosuppressant drugs, patients who received any treatment for wart in the last month before the study.
Sites / Locations
- SohagRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
group 1
group 2
will be treated with intralesional injection of acyclovir (Acyclovir 250mg Powder for Solution for Infusion, each vial contains 250mg of acyclovir as the sodium salt, Chandra Bhagat Pharma Pvt. Ltd) 250 mg acyclovir vial diluted with 3.5 ml saline to get approximately 70 mg/ml solution. During the study, the dosage of the drug and frequency of treatment were uniform in all patients. The base of each wart was injected with 0.1 ml of intralesional acyclovir (70 mg/ml) using an insulin syringe (29 Gage × 0.5-in) every 2 weeks until the resolution of warts or for a maximum of 5 sessions
will be treated by intralesional Candida antigen injection (candida antigen ) at a dose of 0.2 mL. injected into the largest wart using an insulin syringe (29 Gage × 0.5-in) every 2 weeks until complete clearance of warts or for a maximum of 5 treatment sessions.